JAK-Inhibitors in Dermatology: Current Evidence and Future Applications

December 2018 in “ Journal of dermatological treatment ”

Piotr Ciechanowicz, Adriana Rakowska, Mariusz Sikora, Lidia Rudnicka

JAK-inhibitors psoriasis alopecia areata atopic dermatitis vitiligo topical application oral administration

TLDR JAK-inhibitors are effective for treating psoriasis and show promise for other skin diseases.

The publication reviewed the efficacy and safety of JAK-inhibitors in treating skin diseases like psoriasis, alopecia areata, atopic dermatitis, and vitiligo. It analyzed 17 articles, including 11 randomized clinical trials, and found the strongest evidence for JAK-inhibitors in treating psoriasis. There was also potential efficacy noted for alopecia areata, atopic dermatitis, and vitiligo. JAK-inhibitors were mostly used orally, but some studies showed effectiveness with topical application in psoriasis and vitiligo. The review highlighted the need for further research, particularly head-to-head comparison studies with existing treatments.

View this study on tandfonline.com →

Discuss this study in the Community →

Cited in this study

9 / 9 results

research JAK Inhibitors in Dermatology: The Promise of a New Drug Class

355 citations , April 2017 in “Journal of the American Academy of Dermatology”

JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.

research Two Cases of Alopecia Areata Treated with Ruxolitinib: A Discussion of Ideal Dosing and Laboratory Monitoring

25 citations , March 2017 in “International Journal of Dermatology”

Ruxolitinib effectively and safely regrows hair in alopecia patients.

research Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients

238 citations , January 2017 in “Journal of The American Academy of Dermatology”

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

research Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata

196 citations , September 2016 in “JCI insight”

Ruxolitinib effectively regrows hair in most patients with severe hair loss.

research Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata

222 citations , September 2016 in “JCI insight”

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

research Treatment of an Alopecia Areata Patient with Tofacitinib Results in Regrowth of Hair and Changes in Serum and Skin Biomarkers

70 citations , July 2016 in “Experimental Dermatology”

A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.

research Rapid Skin Repigmentation on Oral Ruxolitinib in a Patient with Coexistent Vitiligo and Alopecia Areata

157 citations , February 2016 in “Journal of the American Academy of Dermatology”

A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.

research Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib

184 citations , April 2015 in “EBioMedicine”

A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.

research Vitiligo: A Comprehensive Overview

532 citations , September 2011 in “Journal of the American Academy of Dermatology”

Vitiligo is a skin condition causing white spots, more common in women, often starts before age 20, and can affect mental health.

1 / 1 results

research Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib

4 citations , July 2018 in “PubMed”

Oral and topical tofacitinib can help regrow hair in people with severe alopecia areata.